Axillary lymph node dissection has long been the conventional approach for managing metastasis in regional lymph nodes, often involving the removal of numerous lymph nodes in the armpit to eliminate residual cancer and reduce recurrence risk. However, ALND is frequently associated with significant postoperative complications, most notably lymphoedema—a chronic and frequently debilitating swelling of the arm caused by lymphatic fluid accumulation due to disrupted lymphatic drainage. The prospect of radiotherapy as a substitute aims to mitigate these morbidity risks while maintaining oncological efficacy.

The ADARNAT trial concentrated on patients who had undergone neoadjuvant systemic therapies, such as chemotherapy or hormone therapy, prior to surgery. These treatments often reduce tumor size and eradicate metastasis in lymph nodes, leaving only a limited number of sentinel lymph nodes positive for cancer at the time of surgery. This specific subset—patients with one or two involved sentinel nodes post-neoadjuvant therapy—might not derive significant added benefit from extensive surgical removal of axillary nodes, which potentially subjects patients to unnecessary side effects.

Between mid-2021 and early 2023, the trial enrolled 272 patients diagnosed with breast cancer exhibiting metastasis in only one or two sentinel lymph nodes following systemic therapy. Participants were randomized to receive either axillary radiotherapy or conventional surgical dissection, with both groups receiving radiation to the breast and chest regions. The median follow-up period was two years, a critical window for assessing short-term oncologic safety and adverse effects.

Intriguingly, no axillary cancer recurrences were detected among patients treated with ART, whereas a single recurrence (about 1.8%) was identified in the ALND group. Rates of distant metastasis were comparable between the two cohorts—4.4% in the ART arm and 5.5% with ALND—further suggesting equivalency in systemic disease control. Mortality within this follow-up was low and slightly favored the ART group. Importantly, lymphoedema incidence, while not statistically significant, trended lower in patients receiving radiotherapy (18.9% versus 26.7% in the surgical arm), implying a clinical benefit in terms of reducing this common complication.

Beyond cancer control, the nature and severity of treatment-related toxicities form a crucial consideration. The study observed a higher frequency of acute skin reactions in the ART group, with 27.8% experiencing grade 2 or worse dermatitis compared to 13.3% following ALND. Manifestations included erythema, pigmentation changes, and peeling. However, these reactions were transient and manageable, and no significant long-term dermatologic differences were noted between groups.

Functional outcomes, specifically arm mobility, were also evaluated. Mild, transient impairments in arm elevation and lateral movement occurred slightly more often in ART patients but did not affect daily activities significantly. Measures of quality of life aligned closely between the arms, with a subtle trend favoring those receiving radiotherapy. These data collectively support the contention that axillary radiotherapy offers a feasible, less morbid alternative with qualitatively similar patient experience post-treatment.

Principal investigator Professor Amparo Garcia-Tejedor underscored the preliminary nature of these results, cautioning against hastily changing clinical practice prior to the completion of the full phase III trial. Yet, she indicated that these findings lay the foundational rationale for de-escalating axillary surgery in favor of radiotherapy, especially in patients demonstrating good response to neoadjuvant therapy.

Dr. Maria Laplana-Torres, radiation oncologist and trial co-presenter, emphasized the importance of this ongoing research in refining personalization of breast cancer care. The ability to tailor axillary treatment intensity based on individual disease burden promises to minimize adverse effects without compromising cancer outcomes. Such advances align with the broader movement toward more precise, patient-centered oncology protocols.

Looking ahead, the main phase III segment has already enrolled over 500 patients and aims for robust statistical power to definitively assess long-term survival, recurrence, and quality of life metrics over a planned five-year follow-up. If the final data mirror current trends, it could herald a substantive paradigm shift—encouraging clinicians to favor radiotherapy over surgery in selected populations, thereby sparing many women from the lifelong burden of lymphoedema and other surgical complications.

The chair of the conference, Professor Isabel Rubio, echoed the cautious optimism permeating the breast oncology community. She highlighted that while the pilot data encourage pursuit of less invasive alternatives, further stratification of patients to identify those who might safely omit both surgery and radiation is a promising frontier. Ultimately, such innovation could revolutionize axillary management, balancing oncologic safety with enhanced patient quality of life.

This evolving evidence base underscores the critical imperative of well-designed randomized controlled trials to delineate optimal treatment strategies in an era increasingly defined by precision medicine. The ADARNAT trial represents a significant step forward in understanding how to safely reduce the morbidity burden associated with breast cancer treatment without compromising the ultimate goal—eliminating cancer and prolonging survival.

Subject of Research: People

Image Credits: ADARNAT team

Keywords: Breast cancer, Breast carcinoma, Surgery, Cancer treatments, Radiation therapy, Surgical procedures, Personalized medicine, Side effects, Physical rehabilitation

The newly published observational study sheds light on the potential benefits of polyurethane-coated breast implants as compared to standard silicone implants without such coating. Polyurethane, a polymer with a spongy texture, forms a unique outer shell around these specialized implants. This structural modification appears to substantially mitigate the scarring response that leads to capsular contracture, offering improved long-term surgical outcomes for women receiving adjuvant radiotherapy.

Conducted jointly by experts from leading European medical institutions including the Medical University of Vienna and the University Hospital Basel, the study retrospectively analyzed data from 1,455 women diagnosed with breast cancer between 2016 and 2024. All participants underwent mastectomy followed by immediate breast implant reconstruction and subsequent radiotherapy. Within the cohort, 475 women received polyurethane-coated implants, while 980 were implanted with traditional silicone devices lacking this specialized coating.

Over an extended postoperative follow-up period ranging from two and a half to three years, the incidence of capsular contracture and related complications were meticulously tracked. Results demonstrated a remarkable reduction in scar tissue formation among recipients of polyurethane-coated implants. Specifically, only 32.8% of women in this group developed signs of capsular contracture, in stark contrast to the 47.5% incidence observed in the non-coated implant group. Moreover, the need for secondary surgical interventions to excise or correct scar tissue was nearly threefold lower in the polyurethane cohort (9.3% vs. 25.7%).

Beyond scar formation, rates of major post-surgical infections and urgent implant removals were also notably diminished in the polyurethane-implant patients. These findings suggest that the physical and chemical properties of the polyurethane coating may favorably influence the host’s biological response, attenuating the excessive fibrotic scar formation that is exacerbated by radiation. The surface texture and molecular interactions likely contribute to reduced fibroblast activation and altered immune cell recruitment, although detailed mechanistic studies remain to be conducted.

Dr. Kerstin Wimmer, the lead presenter and surgeon affiliated with both the Medical University of Vienna and the Karolinska Institutet, underscored the clinical significance of these results. She articulated that while the benefits of polyurethane-coated implants have been hinted at in previous smaller trials, this large, real-world study provides robust evidence supporting their use particularly in patients anticipated to receive radiotherapy—a patient population historically burdened with high complication rates.

Despite the encouraging findings, the study’s retrospective design introduces inherent limitations such as selection biases and confounding variables. Treatments were not randomly assigned, and implant choice was influenced by surgeon preference, implant availability, and patient-specific considerations. Nonetheless, the consistency of the observed benefits across multiple international centers, spanning 26 clinical sites across 15 countries, lends credence to the reproducibility of the outcomes.

The current research has earned prestigious acclaim, receiving the EBCC15 Multidisciplinary Team Award for its comprehensive contribution to breast cancer care optimization. Importantly, these findings were generated within the Oncoplastic Breast Consortium, a global research network uniting breast surgeons and oncologists to innovate surgical techniques and improve long-term patient outcomes.

Experts unaffiliated with the study, such as Professor Isabel Rubio of the Clínica Universidad de Navarra, emphasized the potential paradigm shift these data represent. Capsular contracture remains a vexing obstacle in reconstructive breast surgery, severely impacting quality of life due to discomfort, visual deformity, and additional surgeries. If validated by future prospective, randomized clinical trials, the routine adoption of polyurethane-coated implants may meaningfully enhance both aesthetic results and patient comfort while reducing healthcare costs associated with revision surgeries.

With the steady advancement of personalized medicine in breast oncology, integrating implant type considerations into individualized treatment planning could be transformative. Decisions regarding implant selection are multifactorial, encompassing surgeon expertise, regulatory environments, implant accessibility, patient anatomy, and economic factors. Polyurethane-coated implants have a longstanding safety profile and, coupled with improved outcomes demonstrated here, strongly advocate for broader clinical acceptance.

Recognizing that every medical device carries some risk of complications, vigilant postoperative monitoring remains paramount. This includes long-term surveillance for rare adverse effects and ensuring any issues are promptly addressed. The incorporation of these novel implant technologies aligns with ongoing efforts to optimize survivorship care in breast cancer patients, ultimately extending benefits beyond cancer eradication to encompass functional restoration and patient well-being.

In summary, this landmark observational analysis presents compelling clinical evidence that polyurethane-coated breast implants significantly reduce the incidence of capsular contracture and subsequent corrective surgeries in breast cancer patients undergoing radiotherapy after mastectomy. These findings not only enhance our understanding of implant-host interactions in irradiated tissue but also offer new hope for improving reconstructive outcomes, shifting the standard of care toward more durable and patient-centered solutions.

Subject of Research: People

Article Title: Polyurethane-Coated Breast Implants Dramatically Reduce Radiation-Induced Capsular Contracture Risk Following Mastectomy

News Publication Date: June 2024

Web References:

• https://www.europeanbreastcancer.org/ebcc15
• https://oncoplasticbreastconsortium.org

References:

• Wimmer K, Weber W, Fitzal F, Kiblawi R, et al. Observational study of capsular contracture risk following radiotherapy in breast reconstruction with polyurethane-coated versus standard implants. Presented at EBCC15, Barcelona, 2024.

Keywords: Breast cancer, breast reconstruction, mastectomy, polyurethane-coated implants, capsular contracture, radiotherapy, implant complications, reconstructive surgery, fibrosis, observational study